Harlfinger Julia, Sommer Isolde, Gartlehner Gerald
Department für Evidenzbasierte Medizin und Klinische Epidemiologie, Donau-Universitat Krems Department für Evidenzbasierte Medizin und Evaluation, Krems, Austria.
Cochrane Österreich, Department für Evidenzbasierte Medizin und Evaluation, Universität für Weiterbildung Krems, Krems an der Donau, Austria.
Gesundheitswesen. 2023 Jul;85(7):630-634. doi: 10.1055/a-2052-6652. Epub 2023 Jul 12.
Cervical cancer is a major health concern worldwide. Cancer screenings for secondary prevention aim at reducing morbidity and mortality among women. Objective The guideline provides both an updated and an extended overview for the prevention of cervical cancer by screening and therapy.
The World Health Organization (WHO) developed this guideline in accordance with WHO standards. The respective executive summary was translated by a team of Austria's WHO Collaborating Centre.
The updated and extended guideline contains 23 recommendations and seven good practice statements which address screening methods, test regimens, age groups, screening intervals and other topics. Target populations are adult females without known risk factors (general population) and women living with HIV. It is recommended that women from the general population undergo screening every five to ten years, starting at the age of 30. Women living with HIV are advised to get screened every three to five years, starting at the age of 25. Preferred primary screening tests are HPV DNA tests which may be supplemented with further tests in order to triage for further interventions.
宫颈癌是全球主要的健康问题。二级预防的癌症筛查旨在降低女性的发病率和死亡率。目的:本指南为通过筛查和治疗预防宫颈癌提供了最新且全面的概述。
世界卫生组织(WHO)按照WHO标准制定了本指南。相应的执行摘要由奥地利WHO合作中心的一个团队翻译。
更新且全面的指南包含23条建议和7条良好实践声明,涉及筛查方法、检测方案、年龄组、筛查间隔及其他主题。目标人群为无已知风险因素的成年女性(一般人群)和感染艾滋病毒的女性。建议一般人群中的女性从30岁开始每五至十年进行一次筛查。建议感染艾滋病毒的女性从25岁开始每三至五年进行一次筛查。首选的初次筛查检测是HPV DNA检测,可辅以进一步检测以便进行进一步干预的分类。